Antengene Corporation (06996.HK) saw its stock price soar by 13.82% during Friday's trading session, as part of a broader rally in Hong Kong's biotech sector. The significant uptick in Antengene's shares comes amid a wave of investor optimism sweeping through the biotech industry.

The surge in Antengene's stock price was not an isolated incident. Several other biotech companies listed in Hong Kong experienced substantial gains on the same day. Cutia Therapeutics led the pack with a 14% increase, while HBM Holdings and TransThera Sciences both saw their shares climb by 9%. Other notable performers included RemeGen with an 8% rise, CARsgen Therapeutics up 7%, and industry giant WuXi Biologics advancing by 6%.

While specific catalysts for Antengene's individual performance were not immediately clear, the collective upward movement in the biotech sector suggests a broader market trend. Investors appear to be showing renewed interest in biotech stocks, possibly driven by positive industry developments or a general rotation into growth-oriented sectors. As the biotech industry continues to innovate and develop new therapies, companies like Antengene may benefit from increased investor attention and capital inflows.